Latham & Watkins Advises on Cambridge Epigenetix US$88 Million Series D Round

London emerging companies team represents lead investor in financing to advance best-in-class DNA sequencing technology platform.

Latham & Watkins advised the lead investor in Cambridge Epigenetix’s, a life sciences tools and technology company revolutionizing genome sequencing, US$88 million Series D financing, bringing its total funds raised to date to US$146 million.

Proceeds from the financing will be used to commercialize Cambridge Epigenetix’s proprietary genetic and epigenetic sequencing technology, which easily integrates into existing sequencing platforms to enable more information to be read from DNA.

The Latham team was led by London corporate partner Mike Turner, with associate Samantha Si.